- WuXi Biologics has launched PatroLab™, a digital twin platform combining real-time monitoring, Raman-based PAT and in-silico modelling for biologics development and manufacturing.
- The platform is designed to improve process control, reduce risk, shorten timelines and support consistent GMP manufacturing.
WuXi Biologics has announced the launch of PatroLab™, a digital twin platform aimed at supporting bioprocess development and manufacturing. The company said the system integrates real-time process monitoring, Raman-based Process Analytical Technology (PAT) and predictive in-silico modelling to enable smarter analytics, proactive control and faster decision-making across biologics programmes.
According to the company, PatroLab™ is designed to enhance process performance, minimise process risk and shorten development timelines while maintaining consistent product quality. The platform forms part of WuXi Biologics’ digital ecosystem and is intended to support clients from development through to commercial GMP manufacturing within a CDMO and contract manufacturing framework.
“As a leading global digital CRDMO partner, WuXi Biologics aims to turn the complex journey of biologics R&D and manufacturing into a predictable, accelerated success by building an industry-leading digital ecosystem rooted in our biologics expertise.”
Dr. Chris Chen, CEO of WuXi Biologics
A central component of the platform is an advanced Raman PAT system that enables real-time, non-invasive monitoring of more than 40 process performance and product quality attributes. WuXi Biologics said this approach increases data density per batch by nearly 1,000 times compared with traditional off-line testing and supports the application of Quality by Design principles.
The company added that PatroLab™ supports predictive modelling, “what-if” scenario analysis and real-time release testing in line with regulatory guidance. By reducing process deviations and batch variability, the platform is intended to improve manufacturing consistency, reliability and turnaround times for biologics production.
